An unsound AAN Practice Advisory on poststroke etanercept

Perispinal etanercept advances as a neurotherapeutic

“…When in excess, TNF interferes with neurotransmission, perturbs brain function, and mediates neuropathic pain [2][3][4][5][6][7][8][9]. Excess TNF is centrally involved in the initiation and maintenance of neuroinflammation, an area of accelerating interest in the field of neurology [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Bioengineered TNF inhibitors are natural candidates for study in clinical trials of neuroinflammatory disorders .…”

“…Other recent developments have also been significant. There is increasing recognition in the scientific community of the role of excess TNF in the pathophysiology of neuroinflammation, with hundreds of citations to scientific publications involving PSE treatment for spinal pain, AD, stroke, and TBI [1][2][3][4][5][6][7][8][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. A Google Scholar search of 'PSE' currently yields 680 results, one measure of the scholarly interest that these scientific publications have generated.…”

“…Unfamiliarity with CSVS anatomy and physiology has been a barrier to widespread recognition of perispinal administration as a viable method for CNS drug delivery, but this barrier is being overcome through education and the publications of independent scientists [2,6,7,12,15,17,20,21,24,27,29,30]. As one example of this progress, in 2015 PSE off-label for chronic poststroke neurological dysfunction was recognized by a judicial and state medical board decision to be within the medical standard of care [17]. Supportive scientific data continues to accumulate .…”

Randomized controlled trial validating the use of perispinal etanercept to reduce post-stroke disability has wide-ranging implications

“…In effect, the AAN fell in line behind the Big Pharma patent owners. Their position continues unchanged, despite the validity of the AAN's actions being questioned in an editorial some years ago in Expert Review of Neurotherapeutics [18] and the publication of additional supportive evidence [19,20]. Thus almost all neurologists, following the AAN's advice, have ignored invitations to observe or engage in this work, thereby establishing, for years, a quite unjustified barrier to clinical translation of the perispinal method, with its potential for wide application in disease and research.…”

Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective – a Commentary

“…ClinicalTrial.gov Identifiers NCT02448641 and NCT02416492). In contrast, the perispinal etanercept procedure for countering excess TNF [55,56], the outcome of which SB623 cells evidently mimics, yet does not quote [75] has still not raised any official curiosity within the American Academy of Neurology [76] despite years of requests, spanning the period during which the SB623 open trial was done [77], for members of this Academy to witness it. The numbers treated off-label by this method and witnessed by experienced people have mushroomed since a Californian legal judgment (California Case No.…”